{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+treprostinil&page=3",
    "query": {
      "intervention": "Inhaled treprostinil",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+treprostinil&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+treprostinil&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T14:11:34.278Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00703339",
      "title": "Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Treprostinil sodium for inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lung Biotechnology PBC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 1,
      "start_date": "2008-06",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-11",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703339"
    },
    {
      "nct_id": "NCT05147805",
      "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Treprostinil Palmitil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2022-08-24",
      "completion_date": "2025-03-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05147805"
    },
    {
      "nct_id": "NCT04041648",
      "title": "Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "L606 (Liposomal Treprostinil) Inhalation Solution 51ug",
          "type": "DRUG"
        },
        {
          "name": "L606 Inhalation System",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Pharmosa Biopharm Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 52,
      "start_date": "2018-11-09",
      "completion_date": "2020-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041648"
    },
    {
      "nct_id": "NCT04691154",
      "title": "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension",
        "Pulmonary Hypertension Due to Lung Diseases"
      ],
      "interventions": [
        {
          "name": "L606 inhalation suspension",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-08-01",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691154"
    },
    {
      "nct_id": "NCT07481981",
      "title": "A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Treprostinil Palmitil Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 344,
      "start_date": "2026-07-21",
      "completion_date": "2029-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Santa Barbara, California • Torrance, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07481981"
    },
    {
      "nct_id": "NCT03992755",
      "title": "Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "LIQ861 Inhaled Treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2019-07-18",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992755"
    },
    {
      "nct_id": "NCT07102316",
      "title": "A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TPIP F2",
          "type": "DRUG"
        },
        {
          "name": "TPIP F3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 42,
      "start_date": "2025-08-19",
      "completion_date": "2025-11-03",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07102316"
    },
    {
      "nct_id": "NCT00741819",
      "title": "Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Inhaled treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 73,
      "start_date": "2008-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00741819"
    },
    {
      "nct_id": "NCT07759804",
      "title": "A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension (PAH)"
      ],
      "interventions": [
        {
          "name": "LIQ861 (treprostinil) inhalation powder",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 1,
      "location_summary": "Columbus, Georgia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07759804"
    },
    {
      "nct_id": "NCT01305252",
      "title": "A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension, Pulmonary"
      ],
      "interventions": [
        {
          "name": "treprostinil inhalations",
          "type": "DRUG"
        },
        {
          "name": "tadalafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 21,
      "start_date": "2010-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-09-30T14:11:34.278Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305252"
    }
  ]
}